Evoke Pharma Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Evoke Pharma is forecast to grow earnings and revenue by 117.2% and 55% per annum respectively while EPS is expected to grow by 114.6% per annum.
Anahtar bilgiler
117.2%
Kazanç büyüme oranı
114.6%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 23.7% |
Gelir büyüme oranı | 55.0% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 28 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 32 | 8 | N/A | N/A | 1 |
12/31/2025 | 20 | 1 | N/A | N/A | 1 |
12/31/2024 | 11 | -5 | N/A | N/A | 1 |
6/30/2024 | 8 | -7 | -6 | -6 | N/A |
3/31/2024 | 6 | -7 | -6 | -6 | N/A |
12/31/2023 | 5 | -8 | -5 | -5 | N/A |
9/30/2023 | 4 | -8 | -6 | -6 | N/A |
6/30/2023 | 4 | -8 | -6 | -6 | N/A |
3/31/2023 | 3 | -8 | -7 | -7 | N/A |
12/31/2022 | 3 | -8 | -7 | -7 | N/A |
9/30/2022 | 2 | -8 | -6 | -6 | N/A |
6/30/2022 | 2 | -8 | -11 | -11 | N/A |
3/31/2022 | 2 | -8 | -11 | -11 | N/A |
12/31/2021 | 2 | -9 | -12 | -12 | N/A |
9/30/2021 | 1 | -9 | -12 | -12 | N/A |
6/30/2021 | 0 | -9 | -8 | -8 | N/A |
3/31/2021 | 0 | -14 | -8 | -8 | N/A |
12/31/2020 | 0 | -13 | -7 | -7 | N/A |
9/30/2020 | N/A | -12 | -6 | -6 | N/A |
6/30/2020 | N/A | -12 | -5 | -5 | N/A |
3/31/2020 | N/A | -7 | -5 | -5 | N/A |
12/31/2019 | N/A | -7 | -6 | -6 | N/A |
9/30/2019 | N/A | -7 | -6 | -6 | N/A |
6/30/2019 | N/A | -7 | -6 | -6 | N/A |
3/31/2019 | N/A | -8 | -6 | -6 | N/A |
12/31/2018 | N/A | -8 | -7 | -7 | N/A |
9/30/2018 | N/A | -6 | -8 | -8 | N/A |
6/30/2018 | N/A | -10 | -10 | -10 | N/A |
3/31/2018 | N/A | -9 | N/A | -10 | N/A |
12/31/2017 | N/A | -12 | N/A | -9 | N/A |
9/30/2017 | N/A | -13 | N/A | -7 | N/A |
6/30/2017 | N/A | -11 | N/A | -8 | N/A |
3/31/2017 | N/A | -13 | N/A | -8 | N/A |
12/31/2016 | N/A | -11 | N/A | -9 | N/A |
9/30/2016 | N/A | -12 | N/A | -10 | N/A |
6/30/2016 | N/A | -12 | N/A | -10 | N/A |
3/31/2016 | N/A | -12 | N/A | -10 | N/A |
12/31/2015 | N/A | -12 | N/A | -10 | N/A |
9/30/2015 | N/A | -12 | N/A | -11 | N/A |
6/30/2015 | N/A | -14 | N/A | -12 | N/A |
3/31/2015 | N/A | -14 | N/A | -12 | N/A |
12/31/2014 | N/A | -13 | N/A | -12 | N/A |
9/30/2014 | N/A | -12 | N/A | -11 | N/A |
6/30/2014 | N/A | -9 | N/A | -7 | N/A |
3/31/2014 | N/A | -5 | N/A | -5 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: EVOK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Kazançlar ve Piyasa: EVOK is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: EVOK is expected to become profitable in the next 3 years.
Gelir ve Pazar: EVOK's revenue (55% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: EVOK's revenue (55% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time